Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine.
Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine.
复制标题
使用齐多夫定治疗的获得性免疫缺陷综合征（艾滋病）和卡波西肉瘤患者的贫血和红细胞生成。
DOI：
--
复制
发表时间：
1988
影响因子：
39.2
通讯作者：
A. Fauci
中科院分区：
文献类型：
--
作者：
R. Walker;Robert I. Parker;Joseph A. Kovacs;Henry Masur;H. Lane;Stephanie Carleton;L. Kirk;Harvey R. Gralnick;A. Fauci
我们评估了作为齐多夫定治疗试验的一部分，在患有卡波西肉瘤的获得性免疫缺陷综合征(AIDS)患者中贫血的发展情况。患者被随机分为三个治疗组或安慰剂组。在接受齐多夫定治疗的15名患者中，有6名患者在开始治疗后平均6周出现需要输血的贫血(血红蛋白低于100g/L)。网织红细胞数量的下降是毒性的最早外周血液指标。平均红细胞体积在接受齐多夫定治疗的患者中显着增加，但在贫血患者中保持稳定或仅略有增加。骨髓检查显示纯红细胞再生障碍性贫血2例，红系成熟停滞1例，红系发育不良3例。6例贫血患者中2例有巨幼红细胞生成。第一次输血时测得的促红细胞生成素水平升高。因此，与齐多夫定治疗相关的贫血是由于红细胞发育不良或再生障碍性贫血。
We evaluated the development of anemia as part of a trial of zidovudine therapy in patients with the acquired immunodeficiency syndrome (AIDS) with Kaposi sarcoma. Patients were randomized to one of three treatment groups or a placebo group. Transfusion-requiring anemia (hemoglobin less than 100 g/L) developed in 6 of 15 patients on zidovudine therapy at a mean of 6 weeks after starting treatment. A fall in the reticulocyte count was the earliest peripheral blood indicator of toxicity. Mean corpuscular volume increased markedly in patients on zidovudine therapy not developing anemia yet remained stable or only slightly increased in those who became anemic. Bone marrow examination showed pure red cell aplasia in 2 patients, erythroid maturation arrest in 1, and erythroid hypoplasia in 3. Megaloblastic erythropoiesis was present in 2 of the 6 anemic patients. Erythropoietin levels measured at the time of first transfusion were increased. Thus, the anemia associated with zidovudine therapy is due to red cell hypoplasia or aplasia.